Related Experiment Video

Updated: May 1, 2026

The Intra-Aortic Balloon Pump
06:13

The Intra-Aortic Balloon Pump

Published on: February 5, 2021

27.2K

Contemporary use of β-blockers: clinical relevance of subclassification

Luc Poirier1, Sheldon W Tobe2

  • 1Clinique d'hypertension et département de pharmacie, CHUL, CHU de Québec, Québec, Québec, Canada.

The Canadian Journal of Cardiology
|April 2, 2014
PubMed

Insights

Beta-blockers are a cornerstone for hypertension and heart disease, but their clinical benefits versus other agents require further assessment. This review examines pharmacologic differences to guide optimal beta-blocker selection for hypertension.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Beta-adrenergic receptor blockers (beta-blockers) are established cardiovascular agents used for hypertension and heart disease.
  • They are recommended as first-line treatment for uncomplicated essential hypertension in specific patient groups.
  • Concerns exist regarding their morbidity/mortality outcomes compared to other antihypertensive classes.

Purpose of the Study:

  • To review the heterogeneity of pharmacologic characteristics within the beta-blocker class.
  • To discuss metabolic and hemodynamic differences among beta-blockers.
  • To assess the implications of these differences for optimal hypertension management.

Main Methods:

  • Literature review focusing on pharmacologic properties of beta-blockers.
  • Analysis of studies comparing clinical outcomes of different beta-blocker agents.
  • Discussion of metabolic and hemodynamic profiles.

Main Results:

  • Beta-blockers exhibit significant heterogeneity in their pharmacologic profiles.
  • Metabolic and hemodynamic differences exist within the beta-blocker class.
  • The clinical implications of these variations for patient outcomes are debated.

Conclusions:

  • Understanding the diverse characteristics of beta-blockers is crucial for effective hypertension therapy.
  • Further research is needed to clarify the optimal selection of beta-blockers based on individual patient profiles.
  • Tailoring beta-blocker choice may improve morbidity/mortality outcomes in hypertension management.

More Related Videos

Disrupting Reconsolidation of Fear Memory in Humans by a Noradrenergic β-Blocker08:32

Disrupting Reconsolidation of Fear Memory in Humans by a Noradrenergic β-Blocker

Published on: December 18, 2014

25.3K

Related Concept Videos

Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers01:25

Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers

β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but...
1.7K
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
1.8K
Antihypertensive Drugs: Types of β-Blockers01:28

Antihypertensive Drugs: Types of β-Blockers

β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and...
2.0K
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
1.4K
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
2.3K
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
2.7K